Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Ocugen, Inc. (OCGN)

Ocugen licenses OCU400 gene therapy to Roots Pharmaceutical for Middle East and North Africa

Mixed Impact 3 of 5 product/contract Written later

Ocugen signed an exclusive license agreement with Roots Pharmaceutical Company on October 13, 2026, for its OCU400 gene therapy for retinitis pigmentosa in certain Middle East and North Africa countries. Ocugen will receive up to $4 million in upfront and development payments, up to $255 million in sales milestones, and a 22% royalty on Roots' net sales, and will also supply the product under a separate agreement. On the same day, the board postponed the Special Meeting of Stockholders on the proposal to increase authorized common shares by 250,000,000 to December 22, 2026.

Key points

  • Up-front license fee and development milestones of up to $4 million in aggregate
  • Sales milestone payments of up to $255 million and a 22% royalty on net sales in the Territory
  • Special Meeting on the authorized share increase postponed to December 22, 2026; new record date is October 30, 2026

The filing

CompanyOcugen, Inc. (OCGN)
Form8-K, current report
Filed with the SECOct 14, 2026, 9:22 PM ET
Accession number0001104659-26-115921

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.